Bavarian Nordic stock jumps after U.S. orders 2.5 million more monkeypox vaccine doses

The U.S.-listed shares of Bavarian Nordic A/S
BVNRY,
+2.88%
BAVA,
+0.56%
jumped 2.0% in afternoon trading Friday, after the Denmark-based drug maker said the U.S. government has ordered 2.5 million additional doses of liquid-frozen JYNNEOS, the only monkeypox vaccine approved by the U.S. Food and Drug Administration. The new order comes a day after the FDA completed an inspection of the plant where the two-dose vaccine is manufactured. Bavarian Nordic said the additional orders follows two previous orders from the U.S. Biomedical Advanced Research and Development Authority (BARDA) in in June for 500,000 doses and in July for 2.5 million doses, which including an order in 2020 for 1.4 million doses, brings total deliveries to 6.9 million doses in 2022 and 2023. Bavarian Nordic’s stock has shot up 43.4% over the past three months, while the iShares MSCI Denmark Capped ETF
EDEN,
+1.55%
has lost 13.1% and the S&P 500
SPX,
+1.67%
has shed 12.3%.